No Data
No Data
Health Catalyst Price Target Raised to $13.00/Share From $10.00 by JP Morgan
J.P. Morgan Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $13
J.P. Morgan analyst Anne Samuel maintains $Health Catalyst(HCAT.US)$ with a buy rating, and adjusts the target price from $10 to $13.According to TipRanks data, the analyst has a success rate of 50.5%
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11
CCORF analyst Richard Close maintains $Health Catalyst(HCAT.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 53.0% and a
Buy Rating Affirmed on Health Catalyst Amid Positive Growth and Strategic Initiatives
Health Catalyst to Participate in Upcoming Investor Conferences
Express News | Wishin Expands Relationship With Health Catalyst, Signing Multi-Year Partnership to Migrate to Ninja Universe™ Suite